Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Hematology›Condition·Updated Jul 2, 2026·v1

Chronic Myeloid Leukemia

Chronic myeloid leukemia is a BCR-ABL1-driven myeloproliferative neoplasm that has been transformed by tyrosine kinase inhibitor therapy. Management involves risk-stratified TKI selection, regular molecular monitoring, and consideration of treatment-free remission in patients with sustained deep molecular response. Prognosis is excellent, with near-normal life expectancy for most patients who achieve optimal response milestones.

High Evidence267 references·8,095 words·33 min read·v1
chronic myeloid leukemiaBCR-ABL1tyrosine kinase inhibitorPhiladelphia chromosomehematologyoncologyimatinibdasatinibnilotinibasciminib

Quick Reference

RxDrug of choiceImatinib 400 mg PO daily (first-line for low-risk patients; generic available). Second-generation TKIs (dasatinib, nilotinib, bosutinib) or asciminib are preferred for intermediate/high-risk patients or those seeking treatment-free remission.
AltAlternativesDasatinib 100 mg PO daily, nilotinib 300 mg PO BID, bosutinib 400 mg PO daily, asciminib 80 mg PO daily. For T315I mutation: ponatinib 45 mg PO daily or asciminib.
⊘AvoidNon-dihydropyridine CCBs with nilotinib; strong CYP3A4 inducers with most TKIs; TKIs during pregnancy and breastfeeding (use interferon-alpha instead).
DxTest of choiceQuantitative reverse-transcription PCR (qRT-PCR) for BCR-ABL1 on the International Scale (IS) - for diagnosis and monitoring. Bone marrow biopsy with cytogenetics for initial diagnosis and phase assignment.
ScKey scoreELTS score (age, spleen size, platelet count, peripheral blasts) - preferred for risk stratification in the TKI era.
→When to referRefer to hematologist/oncologist at diagnosis. Consider transplant referral for accelerated/blast phase, T315I mutation not controlled, or failure of two or more TKIs.
CML is a highly treatable chronic leukemia with TKI therapy; select the initial TKI based on risk and comorbidities, monitor BCR-ABL1 every 3 months, and consider TFR after sustained deep molecular response.
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the BCR-ABL1 fusion protein, the product of the Philadelphia chromosome t(9;22). Tyrosine kinase inhibitor (TKI) therapy has transformed CML from a fatal disease into a chronic condition with a near-normal life expectancy for most patients. Management centers on selecting the appropriate first-line TKI based on risk stratification and comorbidities, achieving deep molecular responses, and considering treatment-free remission in eligible patients. This overview provides a concise, clinically actionable guide to the background, evaluation, and management of CML.

Overview and Recommendations

Background

  • •Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm defined by the Philadelphia chromosome, a reciprocal t(9;22)(q34;q11) translocation that generates the constitutively active BCR-ABL1 tyrosine kinase fusion protein. This oncoprotein drives uncontrolled proliferation, reduced apoptosis, and genomic instability through downstream pathways including RAS/MAPK, PI3K/AKT, and JAK/STAT.
  • •Epidemiology: CML has an annual incidence of approximately 2 cases per 100,000 population worldwide, with a median age at diagnosis of 60-65 years and a slight male predominance (male-to-female ratio ~1.3-1.5:1). Prevalence is rising rapidly because TKI therapy has reduced annual mortality from >10% in the pre-TKI era to ~1% with modern treatment; an estimated 150,000 patients are living with CML in the United States as of 2025.
  • •CML progresses through three clinical phases: chronic phase (CP, >90% of new diagnoses, <10% blasts), accelerated phase (AP, 10-19% blasts or basophilia ≥20%), and blast crisis (BC, ≥20% blasts or extramedullary blast proliferation). Phase determines prognosis and treatment intensity; CP carries a 10-year survival >85% with optimal TKI therapy, while BC behaves like acute leukemia and has a poor prognosis.
  • •The BCR-ABL1 fusion is the initiating event and therapeutic target. Leukemic stem cells (LSCs) persist despite TKI therapy through quiescence and activation of Hedgehog signaling, PRMT1, and TIF1β pathways, serving as a reservoir for relapse. Resistance mechanisms include BCR-ABL1 kinase domain mutations (most notably T315I, which confers resistance to imatinib, dasatinib, and nilotinib), clonal evolution, and metabolic reprogramming (Warburg effect).
  • •CML is the paradigm of molecularly targeted cancer therapy. The development of TKIs, from imatinib (IRIS trial, 2001) to second-generation agents (dasatinib, nilotinib, bosutinib) and the STAMP inhibitor asciminib (ASC4FIRST trial, 2024), has produced unprecedented survival gains and established the concept of treatment-free remission (TFR) for patients with sustained deep molecular response.

Evaluation

  • •Suspect CML in any patient with incidental leukocytosis on a complete blood count (CBC), especially when accompanied by basophilia and a left shift showing all stages of granulocyte maturation (myelocytes, metamyelocytes, bands, segmented neutrophils).
  • •Ask about constitutional symptoms: fatigue (60-70%), unintentional weight loss, low-grade fever, night sweats, and abdominal discomfort or early satiety from splenomegaly. Also inquire about easy bruising, bleeding, or bone pain.
  • •Examine for splenomegaly (present in ~50% of newly diagnosed CP-CML), hepatomegaly (~10%), pallor, and signs of bruising. Lymphadenopathy is unusual in CP and should raise suspicion for blast phase or a concurrent process.
  • •Order a CBC with differential and a peripheral blood smear. The hallmark is leukocytosis (median WBC ~100 × 10⁹/L) with basophilia, eosinophilia, and a left shift. Anemia is common (50-60%); platelet count may be elevated (~30%) or decreased. The leukocyte alkaline phosphatase (LAP) score is low, a classic but now rarely performed test.
  • •Confirm the diagnosis with bone marrow aspiration and trephine biopsy. In CP, the marrow is hypercellular (90-100%) with a myeloid:erythroid ratio >10:1, increased small hypolobated megakaryocytes, and prominent basophilia. Immunohistochemistry for CD34, CD117, and MPO helps quantify blasts and assign lineage in advanced phases.
  • •Perform cytogenetic analysis (karyotype or FISH) to detect t(9;22)(q34;q11) and molecular testing by quantitative reverse-transcription PCR (qRT-PCR) for BCR-ABL1 transcripts on the International Scale (IS). qRT-PCR is the preferred method for diagnosis and monitoring due to its sensitivity.
  • •Determine disease phase using the ELN/WHO criteria: chronic phase (<10% blasts in blood or marrow), accelerated phase (10-19% blasts or basophilia ≥20%), or blast crisis (≥20% blasts or extramedullary blast proliferation).
  • •Assess risk using the ELTS score (age, spleen size, platelet count, peripheral blasts), which is recommended by NCCN and ELN over the older Sokal and Hasford scores because it better predicts CML-related death in the TKI era.
  • •Obtain baseline abdominal ultrasound to quantify splenomegaly. Chest imaging (X-ray or CT) is indicated if the patient has respiratory symptoms or a WBC >100 × 10⁹/L to evaluate for leukostasis or pulmonary infiltrates.
  • •Evaluate comorbidities, especially cardiovascular, renal, and hepatic function, before selecting a TKI, as each agent has a distinct toxicity profile (e.g., dasatinib: pleural effusion; nilotinib: hyperglycemia, QT prolongation, arterial occlusive events; ponatinib: arterial thrombosis).
  • •Consider BCR-ABL1 kinase domain mutation testing (by Sanger sequencing or next-generation sequencing) at the time of treatment failure, suboptimal response, or if atypical presentation suggests resistance. The T315I mutation requires a third-generation TKI (ponatinib or asciminib).
  • •Also consider differential diagnoses: leukemoid reaction (usually no basophilia, high LAP score), other myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis), and acute leukemias (if blasts are elevated).

Management

  • •Initiate TKI therapy promptly after diagnosis of chronic-phase CML. First-line options include imatinib 400 mg PO once daily, dasatinib 100 mg PO once daily, nilotinib 300 mg PO twice daily, bosutinib 400 mg PO once daily, and asciminib 80 mg PO once daily. All are NCCN Category 1 options; choice is individualized based on ELTS risk score, comorbidities, and the goal of treatment-free remission (TFR).
  • •For low-risk ELTS patients without a TFR goal, generic imatinib is a cost-effective option. For intermediate- or high-risk patients, or those who prioritize TFR, a second-generation TKI (dasatinib, nilotinib, bosutinib) or asciminib is preferred due to faster and deeper molecular responses.
  • •Monitor BCR-ABL1 transcripts by qRT-PCR (IS) every 3 months until a stable deep molecular response (MR4.5, BCR-ABL1 ≤0.0032% IS) is achieved, then every 3-6 months. Optimal response milestones: BCR-ABL1 ≤10% at 3 months, ≤1% at 6 months, and ≤0.1% (major molecular response, MMR) by 12 months.
  • •If a patient fails to achieve these milestones or loses a previously achieved response, first assess adherence and drug-drug interactions. Then perform BCR-ABL1 kinase domain mutation testing. For the T315I mutation, switch to ponatinib 45 mg PO once daily (reduce to 30 or 15 mg for toxicity) or asciminib. For other mutations, select an alternative TKI based on the mutation profile and prior toxicity.
  • •For patients with sustained MR4.5 for ≥2 years, consider TFR after shared decision-making. The EURO-SKI trial reported 61% maintained MMR at 6 months and 46% at 5 years after stopping TKI. Monitor monthly for the first 6 months, then every 2-3 months; restart TKI immediately if MMR is lost.
  • •Manage TKI-specific toxicities: dasatinib - monitor for pleural effusion (35-50% incidence); consider dose reduction to 50 mg daily or switch. Nilotinib - monitor for hyperglycemia, pancreatitis, QT prolongation, and arterial occlusive events; avoid with strong CYP3A4 inhibitors and non-dihydropyridine CCBs. Bosutinib - diarrhea and transaminitis; dose reduce or hold. Ponatinib - arterial thrombotic events (up to 25%); use lowest effective dose and monitor vascular status. Asciminib - pancreatitis, hypertension, rash.
  • •Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) with nilotinib due to QT prolongation risk. Avoid strong CYP3A4 inducers (e.g., rifampin, phenytoin) with most TKIs; use with caution with strong inhibitors.
  • •For accelerated or blast phase CML, initiate a second-generation TKI or ponatinib, and evaluate for allogeneic hematopoietic cell transplantation (HCT) as soon as possible. Blast phase may require acute leukemia-type induction chemotherapy in addition to TKI.
  • •Allogeneic HCT is a curative option for eligible patients who fail multiple TKIs, have the T315I mutation not controlled by ponatinib/asciminib, or present in advanced phase. Transplant-related mortality has declined but remains significant (~10-20%).
  • •For pregnant patients: discontinue TKI upon recognition of pregnancy. Interferon-alpha is the safest option for disease control during pregnancy, with no reported teratogenicity. TKIs are contraindicated during breastfeeding.
  • •For elderly patients (median age at diagnosis 67 years): standard TKI dosing is appropriate, but dose reduction may improve tolerability without compromising efficacy. Low-dose dasatinib 50 mg daily has shown comparable outcomes with fewer adverse events.
  • •Refer to a hematologist/oncologist for initial diagnosis and management. Consider early transplant referral for patients with advanced phase or TKI failure. For TFR candidates, involve the patient in shared decision-making about the risks and benefits of discontinuation.

Board Review — High Yield

  • •Philadelphia chromosome - t(9;22)(q34;q11) resulting in BCR-ABL1 fusion; diagnostic hallmark of CML.
  • •T315I mutation - 'gatekeeper' mutation conferring resistance to imatinib, dasatinib, and nilotinib; treat with ponatinib or asciminib.
  • •ELTS score - preferred risk stratification tool in TKI era (age, spleen size, platelets, blasts).
  • •MMR (major molecular response) - BCR-ABL1 ≤0.1% IS; key milestone by 12 months associated with excellent long-term outcomes.
  • •MR4.5 - deep molecular response (BCR-ABL1 ≤0.0032% IS); prerequisite for treatment-free remission.
  • •IRIS trial - landmark trial establishing imatinib as first-line therapy; CCyR 87% at 5 years, OS 89%.
  • •ASC4FIRST trial - asciminib superior to investigator-selected TKI for MMR at 48 weeks (67.7% vs 49.0%) with better safety.
  • •Treatment-free remission (TFR) - feasible in patients with sustained MR4.5 ≥2 years; ~50% maintain MMR at 5 years after stopping TKI.
  • •Dasatinib toxicity - pleural effusion (35-50%); consider dose reduction or switch.
  • •Ponatinib toxicity - arterial occlusive events (up to 25%); use lowest effective dose.

Deep Dive — Evidence Details

References

  1. [1]

    Cortes JE, Saglio G, Kantarjian HM et al.. “Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27217448 ↗

    L1RCTCited in: Definition and Epidemiology, Management Overview, History and Evolution of Treatment, Special Populations
  2. [2]

    Cortes JE, Gambacorti-Passerini C, Deininger MW et al.. “Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29091516 ↗

    L1RCTCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  3. [3]

    Hehlmann R, Müller MC, Lauseker M et al.. “Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24297946 ↗

    L1RCTCited in: Definition and Epidemiology, Risk Factors and Prevention
  4. [4]

    Castagnetti F, Gugliotta G, Baccarani M et al.. “Differences among young adults, adults and elderly chronic myeloid leukemia patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25361995 ↗

    L2TRIAL_NONRANDOMCited in: Definition and Epidemiology, Management Overview, Special Populations
  5. [5]

    Castagnetti F, Testoni N, Luatti S et al.. “Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20439635 ↗

    L2TRIAL_NONRANDOMCited in: Definition and Epidemiology, Clinical Presentation
  6. [6]

    Casey M, Odhiambo L, Aggarwal N et al.. “Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35944216 ↗

    L2TRIAL_NONRANDOMCited in: Definition and Epidemiology, Risk Factors and Prevention, History and Evolution of Treatment
  7. [7]

    Branford S, Kim DW, Soverini S et al.. “Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 23109697 ↗

    L2TRIAL_NONRANDOMCited in: Definition and Epidemiology
  8. [8]

    Yakoub-Agha I, Mesnil F, Kuentz M et al.. “Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 17116940 ↗

    L2COHORTCited in: Definition and Epidemiology
  9. [9]

    Raanani P, Shpilberg O, Ben-Bassat I. “Extramedullary disease and targeted therapies for hematological malignancies--is the association real?” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16790518 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview
  10. [10]

    Branford S, Seymour JF, Grigg A et al.. “BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 18056186 ↗

    L2RCTCited in: Definition and Epidemiology, History and Evolution of Treatment
  11. [11]

    Bar M, Radich J. “Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23486457 ↗

    L5OTHERCited in: Definition and Epidemiology
  12. [12]

    Seddighi N, Najafpour M, Riyahi M et al.. “Extracellular vesicles-derived non-coding RNA in leukemias and pre-leukemic syndromes: a systematic review.” Journal of cancer research and clinical oncology (2025). PMID: 41432781 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  13. [13]

    Marcolino MS, Boersma E, Clementino NCD et al.. “Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21310760 ↗

    L2OTHERCited in: Definition and Epidemiology, Management Overview, History and Evolution of Treatment
  14. [14]

    Achir A, Debbarh I, Zoubir N et al.. “Advances in Leukemia detection and classification: A Systematic review of AI and image processing techniques.” F1000Research (2025). PMID: 41200664 ↗

    L1SR_OBSCited in: Definition and Epidemiology
  15. [15]

    Marin D, Ibrahim AR, Lucas C et al.. “Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 22067393 ↗

    L2OTHERCited in: Definition and Epidemiology, Histopathology and Molecular Biology
  16. [16]

    de Lavallade H, Apperley JF, Khorashad JS et al.. “Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18519952 ↗

    L2OTHERCited in: Definition and Epidemiology
  17. [17]

    Goldman JM, Majhail NS, Klein JP et al.. “Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20212247 ↗

    L2OTHERCited in: Definition and Epidemiology, Staging
  18. [18]

    Irons EE, Pfeil KA, Perez JA et al.. “Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records.” EClinicalMedicine (2026). PMID: 41583363 ↗

    L2COHORTCited in: Definition and Epidemiology, Clinical Presentation
  19. [19]

    Chalandon Y, Simonetta F, Masouridi-Levrat S. “How I approach hematopoietic stem cell transplantation for CML in a TKI world.” Blood (2026). PMID: 40354577 ↗

    L5CASE_REPORTCited in: Definition and Epidemiology
  20. [20]

    Fitzmaurice C, Allen C, Barber RM et al.. “Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.” JAMA oncology (2017). PMID: 27918777 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  21. [21]

    Oehler VG, Berman E, Huang IJ. “Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing.” Haematologica (2026). PMID: 41816837 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  22. [22]

    Mostafa M, Elhaddad A, Gad MZ et al.. “Beyond XX and XY, Understanding Sex Differences in Leukemia.” Medical sciences (Basel, Switzerland) (2026). PMID: 41562928 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention
  23. [23]

    Sekar AJ, Sakthivel S, Valsala Gopalakrishnan A et al.. “An Overview of Chronic Myeloid Leukemia Treatment: From Tyrosine Kinase Inhibitors to Novel and Emerging Therapies.” European journal of haematology (2026). PMID: 41528066 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  24. [24]

    Aghel N, Lipton JH. “Cardiovascular Disease in Patients With Chronic Myeloid Leukemia: JACC: CardioOncology State-of-the-Art Review.” JACC. CardioOncology (2025). PMID: 40810715 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  25. [25]

    Kantarjian H, Breccia M, Haddad FG et al.. “Management of chronic myeloid leukemia in 2025.” Cancer (2025). PMID: 40616814 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  26. [26]

    Hughes TP, White DL, Yeung DT. “Asciminib for Philadelphia chromosome-positive leukemias.” Haematologica (2025). PMID: 40568725 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  27. [27]

    Hehlmann R, Lauseker M, Jung-Munkwitz S et al.. “Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21422420 ↗

    L1RCTCited in: Risk Factors and Prevention
  28. [28]

    Branford S, Fernandes A, Shahrin N et al.. “Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CML.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38394774 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation, Management Overview
  29. [29]

    Smith BD, Kasamon YL, Kowalski J et al.. “K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20048335 ↗

    L4TRIAL_NONRANDOMCited in: Risk Factors and Prevention, Special Populations
  30. [30]

    Werk RS, Mehrhoff CJ, Badawy SM. “Quality of Life and Adherence to Tyrosine Kinase Inhibitors Among Pediatric, Adolescent, and Young Adult Chronic Myeloid Leukemia Patients: A Systematic Review.” Pediatric blood & cancer (2025). PMID: 40150890 ↗

    L2SR_OBSCited in: Risk Factors and Prevention
  31. [31]

    de Moraes FCA, Matheus GTFU, Rego LHRM et al.. “Do genetic polymorphisms influence imatinib trough concentrations in patients with chronic myeloid leukemia? A systematic review and meta-analysis.” Expert review of anticancer therapy (2025). PMID: 41367289 ↗

    L1SR_OBSCited in: Risk Factors and Prevention
  32. [32]

    Marin D, Bazeos A, Mahon FX et al.. “Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20385986 ↗

    L2OTHERCited in: Risk Factors and Prevention
  33. [33]

    Hahn T, McCarthy PL, Zhang MJ et al.. “Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18981462 ↗

    L2OTHERCited in: Risk Factors and Prevention
  34. [34]

    Etienne G, Guilhot J, Rea D et al.. “Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 28095277 ↗

    L1OTHERCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  35. [35]

    Khorashad JS, de Lavallade H, Apperley JF et al.. “Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18645191 ↗

    L2OTHERCited in: Risk Factors and Prevention
  36. [36]

    Iurlo A, Breccia M, Stagno F et al.. “Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study.” Hematological oncology (2025). PMID: 40778574 ↗

    L2TRIAL_NONRANDOMCited in: Risk Factors and Prevention, History and Evolution of Treatment
  37. [37]

    Maxson JE, Gotlib J, Pollyea DA et al.. “Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.” The New England journal of medicine (2013). PMID: 23656643 ↗

    L3OTHERCited in: Risk Factors and Prevention
  38. [38]

    Hosseini SM, Peymaninezhad F, Khademi F et al.. “Preclinical and Clinical Evidence on the Efficacy and Cytotoxicity of Curcumin and Curcumin Derivatives in Chronic Myeloid Leukemia: A Systematic Review.” Phytochemical analysis : PCA (2026). PMID: 42067395 ↗

    L1SR_OBSCited in: Risk Factors and Prevention
  39. [39]

    McCarty RD, Trabert B, Kriebel D et al.. “Tattoos and Risk of Hematologic Cancer: A Population-Based Case-Control Study in Utah.” Cancer medicine (2024). PMID: 39444249 ↗

    L3CASE_CONTROLCited in: Risk Factors and Prevention
  40. [40]

    Mahon FX, Etienne G. “Deep molecular response in chronic myeloid leukemia: the new goal of therapy?” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 24166905 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Staging, Management Overview, Prognosis and Prognostic Factors
  41. [41]

    Yin Z, Huang G, Gu C et al.. “Discovery of Berberine that Targetedly Induces Autophagic Degradation of both BCR-ABL and BCR-ABL T315I through Recruiting LRSAM1 for Overcoming Imatinib Resistance.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32098768 ↗

    L4OTHERCited in: Risk Factors and Prevention
  42. [42]

    Al Sulaimani R, Zitoun N, Alothman H et al.. “Safety of Hydroxyurea in Pregnancy: A Systematic Review of the Literature.” Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC (2025). PMID: 40381805 ↗

    L1SR_OBSCited in: Risk Factors and Prevention
  43. [43]

    Katsarou D, Kotanidou EP, Tsinopoulou VR et al.. “Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review.” Current pharmaceutical design (2024). PMID: 39005125 ↗

    L2SR_OBSCited in: Risk Factors and Prevention
  44. [44]

    Ferrari A, Salvesi C, Fonzi E et al.. “Unveiling Cryptic BCR-ABL1 Rearrangements: Diagnostic Challenges and Clinical Impact in Myeloid Malignancies.” International journal of molecular sciences (2025). PMID: 41009384 ↗

    L4CASE_REPORTCited in: Risk Factors and Prevention
  45. [45]

    Ji A, McLean A, Sinha A. “McCune-Albright syndrome: a case of an adult with fibrous dysplasia, severe cardiopulmonary complications, acromegaly, and chronic myeloid leukemia.” JBMR plus (2025). PMID: 40584159 ↗

    L4CASE_REPORTCited in: Risk Factors and Prevention
  46. [46]

    Jambon-Barbara C, Suissa S, Dell'Aniello S et al.. “Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.” Circulation (2026). PMID: 41674449 ↗

    L2OTHERCited in: Risk Factors and Prevention
  47. [47]

    Tasneem A, Singh M, Bairagya HR et al.. “Exploring phytochemical inhibitors of fatty acid elongase ELOVL6 for targeted treatment of chronic myeloid leukemia: A comprehensive network-based drug discovery approach.” Computers in biology and medicine (2025). PMID: 41421092 ↗

    L5OTHERCited in: Risk Factors and Prevention
  48. [48]

    Preudhomme C, Guilhot J, Nicolini FE et al.. “Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.” The New England journal of medicine (2010). PMID: 21175313 ↗

    L1RCTCited in: Histopathology and Molecular Biology, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  49. [49]

    Mohan HM, Aherne CM, Rogers AC et al.. “Molecular pathways: the role of NR4A orphan nuclear receptors in cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22566377 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  50. [50]

    Egeli DB, Hanfstein B, Lauseker M et al.. “SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment.” Leukemia & lymphoma (2021). PMID: 34872441 ↗

    L2RCTCited in: Histopathology and Molecular Biology
  51. [51]

    Crisà E, Nicolosi M, Ferri V et al.. “Atypical Chronic Myeloid Leukemia: Where Are We Now?” International journal of molecular sciences (2020). PMID: 32962122 ↗

    L5CASE_REPORTCited in: Histopathology and Molecular Biology
  52. [52]

    Hino M, Matsumura I, Fujisawa S et al.. “Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.” International journal of hematology (2020). PMID: 32279228 ↗

    L2TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology
  53. [53]

    Dierks C, Beigi R, Guo GR et al.. “Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.” Cancer cell (2008). PMID: 18772113 ↗

    L4OTHERCited in: Histopathology and Molecular Biology, Management Overview
  54. [54]

    Krishnan V, Kim DDH, Hughes TP et al.. “Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers.” Haematologica (2022). PMID: 34615339 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  55. [55]

    Hochhaus A, Baccarani M, Silver RT et al.. “European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.” Leukemia (2020). PMID: 32127639 ↗

    L1REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  56. [56]

    Zhu L, Yi K, Zhou J et al.. “Concurrent NPM1::CCDC28A and BCR::ABL1 fusions in extramedullary blast crisis of chronic myeloid leukemia: A case report and literature review.” Annals of hematology (2025). PMID: 41120674 ↗

    L4CASE_REPORTCited in: Histopathology and Molecular Biology
  57. [57]

    Nies AT, Schaeffeler E, van der Kuip H et al.. “Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 24352644 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  58. [58]

    Mäkelä E, Pavic K, Varila T et al.. “Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33674272 ↗

    L4OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  59. [59]

    Castellino A, Santambrogio E, Rapezzi D et al.. “Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment.” Medicina (Kaunas, Lithuania) (2021). PMID: 34684141 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  60. [60]

    Pratap S, Zhao ZJ. “Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.” Cancer reports (Hoboken, N.J.) (2020). PMID: 32671999 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  61. [61]

    Özgür Yurttaş N, Eşkazan AE. “Novel therapeutic approaches in chronic myeloid leukemia.” Leukemia research (2020). PMID: 32200189 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  62. [62]

    Longhurst AD, Wang K, Suresh HG et al.. “The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2.” eLife (2025). PMID: 39903505 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  63. [63]

    Duan H, Lai Q, Jiang Y et al.. “Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia.” Experimental hematology & oncology (2024). PMID: 39696470 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  64. [64]

    Zhou M, Huang Y, Xu P et al.. “PRMT1 Promotes the Self-renewal of Leukemia Stem Cells by Regulating Protein Synthesis.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024). PMID: 39668478 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  65. [65]

    Komic H, Nilsson MS, Wennström L et al.. “Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia.” Haematologica (2025). PMID: 39157872 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  66. [66]

    Morii M, Kubota S, Iimori M et al.. “TIF1β activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia.” Leukemia (2024). PMID: 38734786 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  67. [67]

    Frankhouser DE, Rockne RC, Uechi L et al.. “State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia.” Leukemia (2024). PMID: 38307941 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  68. [68]

    Shah NP, Bhatia R, Altman JK et al.. “Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38394770 ↗

    L1GUIDELINECited in: Clinical Presentation, Management Overview
  69. [69]

    Deininger MW, Shah NP, Altman JK et al.. “Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 33022644 ↗

    L1GUIDELINECited in: Clinical Presentation, Management Overview, History and Evolution of Treatment
  70. [70]

    Radich JP, Deininger M, Abboud CN et al.. “Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30181422 ↗

    L1GUIDELINECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  71. [71]

    Lipton JH, Chuah C, Guerci-Bresler A et al.. “Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.” The Lancet. Oncology (2016). PMID: 27083332 ↗

    L1RCTCited in: Clinical Presentation, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  72. [72]

    Dao KT, Gotlib J, Deininger MMN et al.. “Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31880950 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation, Management Overview, Special Populations
  73. [73]

    Zwaan CM, Rizzari C, Mechinaud F et al.. “Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23715577 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation, Prognosis and Prognostic Factors
  74. [74]

    Cortes JE, Kantarjian HM, Goldberg SL et al.. “High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19720924 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  75. [75]

    Gangaraju R, Kim SJ, Dong JF et al.. “Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28596255 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Prognosis and Prognostic Factors
  76. [76]

    Badalamenti G, Rodolico V, Fulfaro F et al.. “Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17591808 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Management Overview
  77. [77]

    Zhang M, Fu S, Feng J et al.. “Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.” JAMA oncology (2025). PMID: 40244598 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations
  78. [78]

    Banegas MP, Rivera DR, O'Keeffe-Rosetti MC et al.. “Long-Term Patterns of Oral Anticancer Agent Adoption, Duration, and Switching in Patients With CML.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31590146 ↗

    L3OTHERCited in: Clinical Presentation, Special Populations
  79. [79]

    Pallera A, Altman JK, Berman E et al.. “NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27956535 ↗

    L1OTHERCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations
  80. [80]

    Berman E. “Pregnancy in Patients With Chronic Myeloid Leukemia.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29784750 ↗

    L5OTHERCited in: Clinical Presentation, Management Overview, Special Populations
  81. [81]

    Stenehjem DD, Albright F, Kuo KL et al.. “Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 25099443 ↗

    L4OTHERCited in: Clinical Presentation
  82. [82]

    Agis H, Sperr WR, Herndlhofer S et al.. “Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571).” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17804468 ↗

    L3OTHERCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations
  83. [83]

    Mahon FX, Pfirrmann M, Dulucq S et al.. “European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38471049 ↗

    L1OTHERCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations
  84. [84]

    Shah NP. “Front-Line Treatment Options for Chronic-Phase Chronic Myeloid Leukemia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29206554 ↗

    L5OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  85. [85]

    Bower H, Björkholm M, Dickman PW et al.. “Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27325849 ↗

    L2OTHERCited in: Clinical Presentation
  86. [86]

    Molenaar RJ, Sidana S, Radivoyevitch T et al.. “Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29252123 ↗

    L2OTHERCited in: Clinical Presentation
  87. [87]

    Winn AN, Keating NL, Dusetzina SB. “Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27998234 ↗

    L2OTHERCited in: Clinical Presentation
  88. [88]

    Kenzik KM, Bhatia R, Bhatia S. “Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status.” JAMA oncology (2020). PMID: 31999305 ↗

    L2OTHERCited in: Clinical Presentation, Management Overview
  89. [89]

    Krishnan V, Shyamsunder P, Ong TS. “Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses.” Haematologica (2026). PMID: 41952641 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  90. [90]

    Thielen N, Richter J, Baldauf M et al.. “Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27006491 ↗

    L1OTHERCited in: Clinical Presentation, Prognosis and Prognostic Factors, Special Populations
  91. [91]

    Vigneri P, Stagno F, Stella S et al.. “High BCR-ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28928163 ↗

    L2OTHERCited in: Clinical Presentation
  92. [92]

    Schmitt MW, Pritchard JR, Leighow SM et al.. “Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 30042204 ↗

    L2OTHERCited in: Clinical Presentation
  93. [93]

    Haddad FG, Jabbour E, Sasaki K et al.. “Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis.” Clinical lymphoma, myeloma & leukemia (2026). PMID: 41876352 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation, Management Overview
  94. [94]

    Mizuta R, Seto H, Nishita K et al.. “A case report with histopathological evaluation of nilotinib-associated carotid artery plaque following carotid endarterectomy.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2026). PMID: 42297055 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  95. [95]

    Asees M, Abdalhaq T, Amer J. “Case Report: Chronic myeloid leukemia in a 13-year-old-a rare pediatric case of extreme hyperleukocytosis in chronic phase.” Frontiers in medicine (2026). PMID: 41994446 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  96. [96]

    Sillat MS, Chacko G, Jennifer L. “Intracranial Lesion in a Patient With Chronic Myeloid Leukemia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41740586 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Imaging, Management Overview
  97. [97]

    Obeagu EI. “Immunotherapy 3.0: Breakthroughs Steering the Next Generation of Cancer Control.” Cancer reports (Hoboken, N.J.) (2026). PMID: 42267720 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  98. [98]

    Castellana E, Budau PM, Miglietta C et al.. “Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis.” Therapeutic innovation & regulatory science (2026). PMID: 42115566 ↗

    L2REVIEW_NARRATIVECited in: Clinical Presentation
  99. [99]

    ALTermanini M, Altrmanini O, Al-Mashdali AF et al.. “Review of Bleeding as Initial Presentation in Patients with Chronic Myeloid Leukemia.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2026). PMID: 42041205 ↗

    L3REVIEW_NARRATIVECited in: Clinical Presentation
  100. [100]

    Yolcu A, Haznedaroglu IC. “Evolution of the European LeukemiaNet recommendations for chronic myeloid leukemia.” Expert review of hematology (2026). PMID: 41920307 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  101. [101]

    Song JX, Dian ZJ, Wen Y et al.. “Assessment of the Number and Phenotype of Macrophages in the Human BMB Samples of CML.” BioMed research international (2016). PMID: 27999815 ↗

    L3TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  102. [102]

    Das J, Gill A, Lo C et al.. “A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature.” Frontiers in immunology (2020). PMID: 32431694 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Imaging
  103. [103]

    Allegra A, Petrarca C, Di Gioacchino M et al.. “Electrochemical Biosensors in the Diagnosis of Acute and Chronic Leukemias.” Cancers (2022). PMID: 36612142 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  104. [104]

    Samborska M, Derwich K, Skalska-Sadowska J et al.. “Myeloid sarcoma in children - diagnostic and therapeutic difficulties.” Contemporary oncology (Poznan, Poland) (2017). PMID: 28239280 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  105. [105]

    Sanchez-Paz L, Tirado Zambrana PS, Villa Poza C et al.. “Iron deficiency anemia: an early clinical presentation of cytomegalovirus-induced hemorrhagic colitis in chronic myeloid leukemia patients under dasatinib treatment.” Therapeutic advances in hematology (2024). PMID: 39494242 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis
  106. [106]

    Hägglund H, Yavuz AS, Dreimane A et al.. “Graft-versus-mastocytosis effect after donor lymphocyte infusion: Proof of principle.” European journal of haematology (2020). PMID: 33010068 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Imaging
  107. [107]

    Naous R. “Reliability of cytopathology and ancillary testing modalities in the diagnosis of extramedullary hematopoiesis and sclerosing extramedullary hematopoietic tumor: a 10-year institutional experience.” Journal of the American Society of Cytopathology (2025). PMID: 40157822 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  108. [108]

    Zhang J, Bulterys PL, Fernandez-Pol S et al.. “Expression of CD47 protein in hematolymphoid neoplasms: Implications for CD47-mediated cancer immunotherapy.” American journal of clinical pathology (2025). PMID: 40072022 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  109. [109]

    Signoretto I, Calzetti F, Finotti G et al.. “Uncovering two neutrophil-committed progenitors that immediately precede promyelocytes during human neutropoiesis.” Cellular & molecular immunology (2025). PMID: 39939817 ↗

    L5OTHERCited in: Biopsy and Histologic Diagnosis
  110. [110]

    Li X, Xiao Y, Wang X et al.. “Connexin 43-modified bone marrow stromal cells reverse the imatinib resistance of K562 cells via Ca 2+ -dependent gap junction intercellular communication.” Chinese medical journal (2023). PMID: 36801891 ↗

    L5OTHERCited in: Biopsy and Histologic Diagnosis
  111. [111]

    Morgan RL, Bathala TK, Arora SS et al.. “ACR Appropriateness Criteria® Staging and Follow-Up of Leukemia.” Journal of the American College of Radiology : JACR (2025). PMID: 41193051 ↗

    L1GUIDELINECited in: Imaging, Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors
  112. [112]

    Deandreis D, Maillard A, Zerdoud S et al.. “RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer.” European journal of nuclear medicine and molecular imaging (2021). PMID: 33619600 ↗

    L2TRIAL_NONRANDOMCited in: Imaging
  113. [113]

    Orlikow E, Weatherald J, Hirani N. “Dasatinib-Induced Pulmonary Arterial Hypertension.” The Canadian journal of cardiology (2019). PMID: 31590985 ↗

    L4CASE_REPORTCited in: Imaging
  114. [114]

    Su Z, Wu F, Hu W et al.. “Philadelphia chromosome-positive acute myeloid leukemia with masses and osteolytic lesions: finding of 18F-FDG PET/CT.” Frontiers of medicine (2017). PMID: 28550639 ↗

    L4CASE_REPORTCited in: Imaging
  115. [115]

    Li W, Subedi R, Madhira B. “A cardiac tamponade in the hypertensive patient presenting as abdominal fullness.” The American journal of emergency medicine (2017). PMID: 28237383 ↗

    L4CASE_REPORTCited in: Imaging
  116. [116]

    Abdulhamid MM, Li YM, Hall WA. “Spontaneous acute subdural hematoma as the initial manifestation of chronic myeloid leukemia.” Journal of neuro-oncology (2010). PMID: 20582615 ↗

    L4CASE_REPORTCited in: Imaging
  117. [117]

    Feng X, Yang L, Liu X et al.. “Long non-coding RNA small nucleolar RNA host gene 29 drives chronic myeloid leukemia progression via microRNA-483-3p/Casitas B-lineage Lymphoma axis-mediated activation of the phosphoinositide 3-kinase/Akt pathway.” Medical oncology (Northwood, London, England) (2024). PMID: 38252204 ↗

    L3OTHERCited in: Imaging
  118. [118]

    Shroff GS, Truong MT, Carter BW et al.. “Leukemic Involvement in the Thorax.” Radiographics : a review publication of the Radiological Society of North America, Inc (2019). PMID: 30620703 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  119. [119]

    Sorgun MH, Rzayev S, Yilmaz V et al.. “Etiologic Subtypes of Watershed Infarcts.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2015). PMID: 26375794 ↗

    L4OTHERCited in: Imaging
  120. [120]

    Montano-Campos JF, Hahn EE, Haupt EC et al.. “Shared Identity and Patient Care: Adherence to Guideline-Recommended Biomarker Testing in Chronic Myeloid Leukemia.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 41825119 ↗

    L3OTHERCited in: Molecular Diagnostics and Biomarkers, Special Populations
  121. [121]

    Póvoa VMO, Delafiori J, Dias-Audibert FL et al.. “Metabolic shift of chronic myeloid leukemia patients under imatinib-pioglitazone regimen and discontinuation.” Medical oncology (Northwood, London, England) (2021). PMID: 34302533 ↗

    L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
  122. [122]

    Li AJ, Dhanraj JP, Lopes G et al.. “Clinical trial risk in leukemia: Biomarkers and trial design.” Hematological oncology (2020). PMID: 33078436 ↗

    L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
  123. [123]

    Spiess B, Kleiner H, Flach J et al.. “Separase activity distribution can be a marker of major molecular response and proliferation of CD34+ cells in TKI-treated chronic myeloid leukemia patients.” Annals of hematology (2020). PMID: 32253454 ↗

    L3TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
  124. [124]

    Kim DH, Kong JH, Byeun JY et al.. “The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20959405 ↗

    L3OTHERCited in: Molecular Diagnostics and Biomarkers, Special Populations
  125. [125]

    Luo FR, Yang Z, Camuso A et al.. “Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 17145844 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  126. [126]

    Press RD, Galderisi C, Yang R et al.. “A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17947479 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  127. [127]

    Luciano L, Annunziata M, Attolico I et al.. “The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.” European journal of haematology (2020). PMID: 32145037 ↗

    L5CASE_REPORTCited in: Molecular Diagnostics and Biomarkers
  128. [128]

    Hrdinova T, Kupcova Skalnikova H. “Roles of extracellular vesicles in the pathogenesis of chronic myeloid leukemia.” Journal of physiology and biochemistry (2026). PMID: 41995930 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  129. [129]

    Alhmoud JF, Alqaraleh M, Dala-Ali SN et al.. “Role of Specific miRNA Expression and Nuclear Kappa B Gene Polymorphism as Potential Diagnostic Markers for Chronic Myeloid Leukemia.” Medical principles and practice : international journal of the Kuwait University, Health Science Centre (2026). PMID: 41615870 ↗

    L3OTHERCited in: Molecular Diagnostics and Biomarkers
  130. [130]

    Cayssials E, Lefèvre L, Decroos A et al.. “Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients.” Cancer immunology, immunotherapy : CII (2025). PMID: 41417235 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  131. [131]

    Rea D. “Prognostic factors in chronic myeloid leukemia: at diagnosis and for treatment-free remission.” Haematologica (2025). PMID: 41342177 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  132. [132]

    Bao M, Zhang XS, Li ZR et al.. “Efficacy, safety and predictive biomarker of third-generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia.” Cancer (2025). PMID: 41199590 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers
  133. [133]

    Zhou X, Li A, Kong D et al.. “The silent players: Atypical BCR‑ABL isoforms as biomarkers and therapeutic hurdles in CML pathogenesis (Review).” Oncology reports (2025). PMID: 40999990 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  134. [134]

    Mauro MJ. “Can any patients with chronic myeloid leukemia outside of a clinical trial have their tyrosine kinase inhibitor discontinued?” Current opinion in hematology (2017). PMID: 28099274 ↗

    L5TRIAL_NONRANDOMCited in: Staging
  135. [135]

    Breccia M, Tiribelli M, Alimena G. “Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data.” Critical reviews in oncology/hematology (2012). PMID: 22280914 ↗

    L5SR_OBSCited in: Staging
  136. [136]

    Suttorp M, Schulze P, Glauche I et al.. “Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.” Leukemia (2018). PMID: 29925908 ↗

    L4TRIAL_NONRANDOMCited in: Staging
  137. [137]

    Takahashi K, Kantarjian HM, Yang Y et al.. “A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.” Cancer (2016). PMID: 27509035 ↗

    L2TRIAL_NONRANDOMCited in: Staging
  138. [138]

    Takebayashi K, Sonoda H, Shimizu T et al.. “Pyomyositis at the surgical site in a patient with chronic myeloid leukemia: a case report and literature review.” World journal of surgical oncology (2016). PMID: 27094880 ↗

    L4CASE_REPORTCited in: Staging
  139. [139]

    Nakaseko C, Takahashi N, Ishizawa K et al.. “A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia.” International journal of hematology (2014). PMID: 25540064 ↗

    L4TRIAL_NONRANDOMCited in: Staging
  140. [140]

    Khoury HJ, Cortes J, Baccarani M et al.. “Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.” Leukemia & lymphoma (2014). PMID: 24650054 ↗

    L4TRIAL_NONRANDOMCited in: Staging
  141. [141]

    Jabbour E, Kantarjian H. “Chronic Myeloid Leukemia: A Review.” JAMA (2025). PMID: 40094679 ↗

    L5REVIEW_NARRATIVECited in: Staging
  142. [142]

    Jabbour E, Kantarjian H. “Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.” American journal of hematology (2018). PMID: 29411417 ↗

    L5REVIEW_NARRATIVECited in: Staging
  143. [143]

    Radich JP, Mauro MJ. “Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.” Hematology/oncology clinics of North America (2017). PMID: 28673389 ↗

    L5REVIEW_NARRATIVECited in: Staging
  144. [144]

    Ali MA. “Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.” Molecular diagnosis & therapy (2016). PMID: 27220498 ↗

    L5REVIEW_NARRATIVECited in: Staging
  145. [145]

    Soverini S, Colarossi S, Gnani A et al.. “Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 17189410 ↗

    L4OTHERCited in: Staging, Prognosis and Prognostic Factors, Special Populations
  146. [146]

    Baccarani M, Cortes J, Pane F et al.. “Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19884523 ↗

    L1GUIDELINECited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  147. [147]

    Hochhaus A, Wang J, Kim DW et al.. “Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.” The New England journal of medicine (2024). PMID: 38820078 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  148. [148]

    Hochhaus A, Larson RA, Guilhot F et al.. “Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.” The New England journal of medicine (2017). PMID: 28273028 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations
  149. [149]

    Saglio G, Kim DW, Issaragrisil S et al.. “Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.” The New England journal of medicine (2010). PMID: 20525993 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations
  150. [150]

    Kantarjian H, Shah NP, Hochhaus A et al.. “Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.” The New England journal of medicine (2010). PMID: 20525995 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations
  151. [151]

    Druker BJ, Guilhot F, O'Brien SG et al.. “Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.” The New England journal of medicine (2006). PMID: 17151364 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  152. [152]

    Jabbour E, Oehler VG, Koller PB et al.. “Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.” JAMA oncology (2025). PMID: 39570620 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  153. [153]

    Signorovitch J, Ayyagari R, Reichmann WM et al.. “Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.” Cancer treatment reviews (2013). PMID: 24112812 ↗

    L1SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors
  154. [154]

    Azim HA, Pavlidis N, Peccatori FA. “Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors.” Cancer treatment reviews (2009). PMID: 20018452 ↗

    L5SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  155. [155]

    Brivio E, Pennesi E, Willemse ME et al.. “Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 38033284 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors
  156. [156]

    Hughes TP, Mauro MJ, Cortes JE et al.. “Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.” The New England journal of medicine (2019). PMID: 31826340 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
  157. [157]

    Cortes JE, Kantarjian H, Shah NP et al.. “Ponatinib in refractory Philadelphia chromosome-positive leukemias.” The New England journal of medicine (2012). PMID: 23190221 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
  158. [158]

    Cortes JE, Kim DW, Pinilla-Ibarz J et al.. “A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.” The New England journal of medicine (2013). PMID: 24180494 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, History and Evolution of Treatment, Special Populations
  159. [159]

    Przespolewski ER, Baron J, Kashef F et al.. “Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 36791756 ↗

    L4CASE_REPORTCited in: Management Overview
  160. [160]

    Atallah E, Schiffer CA, Radich JP et al.. “Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.” JAMA oncology (2021). PMID: 33180106 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  161. [161]

    Takahashi N, Kim DW, Kim I et al.. “Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.” Cancer medicine (2026). PMID: 42339511 ↗

    L2RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  162. [162]

    Garcia-Horton A, Lipton JH. “Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All?” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 33022650 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  163. [163]

    Poston JN, Becker PS. “Controversies Regarding Use of Myeloid Growth Factors in Leukemia.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 29223992 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  164. [164]

    Oehler VG, Huang IJ, Siu C et al.. “Dose Modifications in the Management of Chronic Phase Chronic Myeloid Leukemia: Who, What, and When.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39536447 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  165. [165]

    Radich JP, Oehler V. “Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors.” Journal of the National Comprehensive Cancer Network : JNCCN (2007). PMID: 17509253 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  166. [166]

    Kantarjian H, Cortes J. “BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18397680 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  167. [167]

    Cortes J, Kantarjian H. “Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18397678 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  168. [168]

    Haddad FG, Kantarjian H. “Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38394773 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  169. [169]

    Shah NP. “NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31117031 ↗

    L1OTHERCited in: Management Overview, Prognosis and Prognostic Factors
  170. [170]

    Hijiya N, Zwaan CM, Rizzari C et al.. “Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31676669 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  171. [171]

    Khoury HJ, Gambacorti-Passerini C, Brümmendorf TH. “Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29385394 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  172. [172]

    Olivieri A, Manzione L. “Dasatinib: a new step in molecular target therapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17591830 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, History and Evolution of Treatment
  173. [173]

    Li RJ, Zhang GS, Chen YH et al.. “Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 20038517 ↗

    L5OTHERCited in: Management Overview
  174. [174]

    Martinelli G, Iacobucci I, Rosti G et al.. “Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16403813 ↗

    L4OTHERCited in: Management Overview
  175. [175]

    Seong SJ, Lim M, Sohn SK et al.. “Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23117072 ↗

    L4OTHERCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  176. [176]

    Kim DH, Xu W, Kamel-Reid S et al.. “Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19875757 ↗

    L4OTHERCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  177. [177]

    Capdeville R, Krahnke T, Hatfield A et al.. “Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias.” Annals of oncology : official journal of the European Society for Medical Oncology (2008). PMID: 18344535 ↗

    L2OTHERCited in: Management Overview, Special Populations
  178. [178]

    Bixby DL. “Managing inadequate responses to frontline treatment of chronic myeloid leukemia: a case-based review.” Cancer treatment reviews (2012). PMID: 22818213 ↗

    L5CASE_REPORTCited in: Management Overview, Prognosis and Prognostic Factors
  179. [179]

    Kavalerchik E, Goff D, Jamieson CH. “Chronic myeloid leukemia stem cells.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18539972 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  180. [180]

    Moslehi JJ, Deininger M. “Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26371140 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  181. [181]

    Michor F. “Mathematical models of cancer stem cells.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18539964 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, History and Evolution of Treatment
  182. [182]

    Cortes J, Hochhaus A, Hughes T et al.. “Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21220597 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, History and Evolution of Treatment
  183. [183]

    Ault P, Kantarjian H, O'Brien S et al.. “Pregnancy among patients with chronic myeloid leukemia treated with imatinib.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16446320 ↗

    L4OTHERCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  184. [184]

    Wang H, Yang Y, Chen Z et al.. “Effects of a High-Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia.” Clinical and translational science (2026). PMID: 42105274 ↗

    L1TRIAL_NONRANDOMCited in: Management Overview, Special Populations
  185. [185]

    Hochhaus A, le Coutre P, Milojkovic D et al.. “ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.” Leukemia (2026). PMID: 42026180 ↗

    L1TRIAL_NONRANDOMCited in: Management Overview, Special Populations
  186. [186]

    Eide CA, Brewer D, Xie T et al.. “Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.” Cancer cell (2024). PMID: 39214096 ↗

    L4CASE_REPORTCited in: Management Overview
  187. [187]

    Boudny M, Trbusek M. “ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.” Cancer treatment reviews (2020). PMID: 32592909 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  188. [188]

    Brechbiel J, Miller-Moslin K, Adjei AA. “Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.” Cancer treatment reviews (2014). PMID: 24613036 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  189. [189]

    Rosti G, Castagnetti F, Gugliotta G et al.. “Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML.” Cancer treatment reviews (2011). PMID: 21840128 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  190. [190]

    Deol A, Lum LG. “Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.” Cancer treatment reviews (2010). PMID: 20381970 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  191. [191]

    Egan JM. “Targeting Stem Cells in Chronic Myeloid Leukemia with a PPAR-γ Agonist.” The New England journal of medicine (2015). PMID: 26559576 ↗

    L5OTHERCited in: Management Overview
  192. [192]

    Scott MT, Korfi K, Saffrey P et al.. “Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.” Cancer discovery (2016). PMID: 27630125 ↗

    L2OTHERCited in: Management Overview
  193. [193]

    Braun TP, Eide CA, Druker BJ. “Response and Resistance to BCR-ABL1-Targeted Therapies.” Cancer cell (2020). PMID: 32289275 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  194. [194]

    Shah NP, Kasap C, Weier C et al.. “Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.” Cancer cell (2008). PMID: 19061839 ↗

    L2OTHERCited in: Management Overview
  195. [195]

    O'Hare T, Shakespeare WC, Zhu X et al.. “AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.” Cancer cell (2009). PMID: 19878872 ↗

    L2OTHERCited in: Management Overview
  196. [196]

    Eide CA, Zabriskie MS, Savage Stevens SL et al.. “Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.” Cancer cell (2019). PMID: 31543464 ↗

    L2OTHERCited in: Management Overview
  197. [197]

    Packer LM, Rana S, Hayward R et al.. “Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.” Cancer cell (2011). PMID: 22169110 ↗

    L2OTHERCited in: Management Overview
  198. [198]

    Chan WW, Wise SC, Kaufman MD et al.. “Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.” Cancer cell (2011). PMID: 21481795 ↗

    L2OTHERCited in: Management Overview
  199. [199]

    Méndez-Ferrer S, García-Fernández M, de Castillejo CL. “Convert and conquer: the strategy of chronic myelogenous leukemic cells.” Cancer cell (2015). PMID: 25965567 ↗

    L5OTHERCited in: Management Overview
  200. [200]

    Klemm L, Duy C, Iacobucci I et al.. “The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia.” Cancer cell (2009). PMID: 19732723 ↗

    L2OTHERCited in: Management Overview
  201. [201]

    Schmidt T, Kharabi Masouleh B, Loges S et al.. “Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.” Cancer cell (2011). PMID: 21665148 ↗

    L5OTHERCited in: Management Overview
  202. [202]

    Apsel Winger B, Shah NP. “PPARγ: Welcoming the New Kid on the CML Stem Cell Block.” Cancer cell (2015). PMID: 26461088 ↗

    L5OTHERCited in: Management Overview
  203. [203]

    Takeishi S, Matsumoto A, Onoyama I et al.. “Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence.” Cancer cell (2013). PMID: 23518349 ↗

    L5OTHERCited in: Management Overview, History and Evolution of Treatment
  204. [204]

    Strout MP, Schatz DG. “Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.” Cancer cell (2009). PMID: 19732715 ↗

    L5OTHERCited in: Management Overview
  205. [205]

    Breccia M, Giai V, Rosso T et al.. “Age and gender effects on molecular responses in chronic myeloid leukemia patients by first-line treatment: an Italian CML network cohort study.” Annals of hematology (2026). PMID: 41999487 ↗

    L2COHORTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  206. [206]

    Cilloni D, Saglio G. “Molecular pathways: BCR-ABL.” Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 22156549 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  207. [207]

    Awan FT, Byrd JC. “New strategies in chronic lymphocytic leukemia: shifting treatment paradigms.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25294898 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  208. [208]

    Frankfurt O, Licht JD. “Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 23935038 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  209. [209]

    Cortes JE, Abruzzese E, Cardonick EH et al.. “Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are Breastfeeding.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38967550 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Special Populations
  210. [210]

    Cardenas MG, Oswald E, Yu W et al.. “The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27881582 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  211. [211]

    Sweet KL, Cortes JE, Apperley JF et al.. “Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36547666 ↗

    L5OTHERCited in: Management Overview
  212. [212]

    Lovly CM, Shaw AT. “Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24789032 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  213. [213]

    Eechoute K, Sparreboom A, Burger H et al.. “Drug transporters and imatinib treatment: implications for clinical practice.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 21163869 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  214. [214]

    Banerji U. “Heat shock protein 90 as a drug target: some like it hot.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19118027 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  215. [215]

    Müller MC. “New Drug for Chronic Myeloid Leukemia Might Stimulate the Market.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 33109738 ↗

    L5OTHERCited in: Management Overview, History and Evolution of Treatment
  216. [216]

    Kantarjian HM, Baccarani M, Jabbour E et al.. “Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 21307148 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  217. [217]

    Ben-Batalla I, Erdmann R, Jørgensen H et al.. “Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27856601 ↗

    L5OTHERCited in: Management Overview
  218. [218]

    Zhang L, Meng L, Liu B et al.. “Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32928796 ↗

    L1OTHERCited in: Management Overview, Prognosis and Prognostic Factors
  219. [219]

    Bao M, Huang J, Li Z et al.. “Olverembatinib-Based Therapy in Patients With Transformed Chronic Myeloid Leukemia in Lymphoid Blast Phase or Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study.” Clinical lymphoma, myeloma & leukemia (2026). PMID: 41807207 ↗

    L3COHORTCited in: Management Overview
  220. [220]

    Terzi H, Taştemur Ş, Öztürk A et al.. “Apigenin as a Multitarget Anticancer Agent: Coordinated Inhibition of EGFR/MAPK and PI3K/Akt Signaling in Hematologic Malignancies.” International journal of molecular sciences (2026). PMID: 42278191 ↗

    L5OTHERCited in: Management Overview
  221. [221]

    Xu H, Zhang X, Zhang J. “The evolving landscape of regulatory T cells in leukemia: from mechanisms to advanced immunotherapeutic strategies.” Frontiers in immunology (2026). PMID: 42245675 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  222. [222]

    Li F, Lin JF, Tian P et al.. “PRKCA and ABCB1 dual-enriched exosomes are key drivers of drug resistance in chronic myeloid leukemia.” Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy (2026). PMID: 42235483 ↗

    L5OTHERCited in: Management Overview
  223. [223]

    Hochhaus A, Talpaz M, Saglio G et al.. “From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.” Leukemia (2026). PMID: 42174092 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, History and Evolution of Treatment
  224. [224]

    Verhagen NE, Touw DCW, van den Heuvel JJMW et al.. “Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid leukemia.” Cancer chemotherapy and pharmacology (2026). PMID: 42118353 ↗

    L5OTHERCited in: Management Overview
  225. [225]

    Zhou Q, Xu G, Li Z et al.. “Inhibition of Pellino-1 reverts the progression and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.” Cell death & disease (2026). PMID: 42086539 ↗

    L5OTHERCited in: Management Overview
  226. [226]

    Tsubaki M, Matsuo T, Komori R. “Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.” Oncology research (2026). PMID: 42065050 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  227. [227]

    Çelik B, Kiraz Y, Şahin Y et al.. “Targeting STAT5A via CRISPR/Cas9 restores TKI sensitivity in resistant chronic myeloid leukemia cells.” Medical oncology (Northwood, London, England) (2026). PMID: 42033509 ↗

    L5OTHERCited in: Management Overview
  228. [228]

    Cortes JE, Kim DW, Kantarjian HM et al.. “Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22949154 ↗

    L1RCTCited in: History and Evolution of Treatment, Special Populations
  229. [229]

    Cortes JE, Jones D, O'Brien S et al.. “Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 20008620 ↗

    L1RCTCited in: History and Evolution of Treatment, Special Populations
  230. [230]

    Hahn EA, Glendenning GA, Sorensen MV et al.. “Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2003). PMID: 12775739 ↗

    L1RCTCited in: History and Evolution of Treatment
  231. [231]

    Shah NP, Kantarjian HM, Kim DW et al.. “Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18541900 ↗

    L2RCTCited in: History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  232. [232]

    Demetri GD, von Mehren M, Blanke CD et al.. “Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.” The New England journal of medicine (2002). PMID: 12181401 ↗

    L1RCTCited in: History and Evolution of Treatment
  233. [233]

    O'Brien SG, Guilhot F, Larson RA et al.. “Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.” The New England journal of medicine (2003). PMID: 12637609 ↗

    L1RCTCited in: History and Evolution of Treatment
  234. [234]

    Tura S, Baccarani M, Zuffa E et al.. “Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.” The New England journal of medicine (1994). PMID: 8114834 ↗

    L1RCTCited in: History and Evolution of Treatment
  235. [235]

    Guilhot F, Chastang C, Michallet M et al.. “Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.” The New England journal of medicine (1997). PMID: 9227927 ↗

    L1RCTCited in: History and Evolution of Treatment
  236. [236]

    Hughes TP, Kaeda J, Branford S et al.. “Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.” The New England journal of medicine (2003). PMID: 14534335 ↗

    L1RCTCited in: History and Evolution of Treatment
  237. [237]

    McLean LA, Gathmann I, Capdeville R et al.. “Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib.” Clinical cancer research : an official journal of the American Association for Cancer Research (2004). PMID: 14734464 ↗

    L2RCTCited in: History and Evolution of Treatment
  238. [238]

    Kwak JY, Kim SH, Oh SJ et al.. “Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28939746 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Prognostic Factors
  239. [239]

    Palandri F, Iacobucci I, Soverini S et al.. “Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19188180 ↗

    L3TRIAL_NONRANDOMCited in: History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  240. [240]

    Kantarjian HM, Talpaz M, O'Brien S et al.. “Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.” Clinical cancer research : an official journal of the American Association for Cancer Research (2002). PMID: 12114418 ↗

    L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  241. [241]

    Mohamed AN, Pemberton P, Zonder J et al.. “The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.” Clinical cancer research : an official journal of the American Association for Cancer Research (2003). PMID: 12684401 ↗

    L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  242. [242]

    Cayuela JM, Dulucq S, Hayette S et al.. “[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].” Bulletin du cancer (2025). PMID: 40908230 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  243. [243]

    Rea D, Kyrcz-Krzemien S, Sportoletti P et al.. “Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.” Leukemia (2026). PMID: 41555010 ↗

    L1RCTCited in: History and Evolution of Treatment, Special Populations
  244. [244]

    Burchert A, Nicolini FE, le Coutre P et al.. “Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).” Leukemia (2026). PMID: 41526617 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  245. [245]

    Cortes JE, Hughes TP, Wang J et al.. “Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.” Blood (2026). PMID: 41397287 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  246. [246]

    Castagnetti F, Breccia M, Abruzzese E et al.. “Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.” Leukemia (2025). PMID: 41254114 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  247. [247]

    . “[Guideline for the diagnosis and treatment of chronic myeloid leukemia in China (2025)].” Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2025). PMID: 41486652 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  248. [248]

    Hoch M, Weis W, Huth F et al.. “Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants.” Clinical pharmacology in drug development (2025). PMID: 41123847 ↗

    L1TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  249. [249]

    Arteaga CL, Baselga J. “Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?” Cancer cell (2004). PMID: 15193255 ↗

    L5OTHERCited in: History and Evolution of Treatment
  250. [250]

    De Propris MS, Laganà A, Breccia M et al.. “Four Decades of Molecular Innovation in Chronic Myeloid Leukemia: From Antisense Targeting to Treatment-Free Remission.” Cancers (2026). PMID: 42352456 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  251. [251]

    Kosugi N, Ebihara Y, Nakahata T et al.. “CD34+CD7+ leukemic progenitor cells may be involved in maintenance and clonal evolution of chronic myeloid leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2005). PMID: 15701834 ↗

    L5OTHERCited in: History and Evolution of Treatment
  252. [252]

    Maxson JE, Luty SB, MacManiman JD et al.. “The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26475333 ↗

    L4OTHERCited in: History and Evolution of Treatment
  253. [253]

    O'Hare T, Deininger MW, Eide CA et al.. “Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 21098337 ↗

    L5OTHERCited in: History and Evolution of Treatment
  254. [254]

    Gore L, Kearns PR, de Martino ML et al.. “Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29498925 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
  255. [255]

    Apperley JF, Cortes JE, Kim DW et al.. “Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19487385 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors, Special Populations
  256. [256]

    Cortes J, Goldman JM, Hughes T. “Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure.” Journal of the National Comprehensive Cancer Network : JNCCN (2012). PMID: 23055247 ↗

    L5OTHERCited in: Prognosis and Prognostic Factors
  257. [257]

    Iacobucci I, Saglio G, Rosti G et al.. “Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16707599 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors, Special Populations
  258. [258]

    Tuerxun A, Yang Y, Cai X et al.. “Prediction models for different types of leukemia: a systematic review and critical appraisal.” Journal of cancer research and clinical oncology (2025). PMID: 41014388 ↗

    L2SR_OBSCited in: Prognosis and Prognostic Factors
  259. [259]

    Fan Z, Chen QW, Huang XY et al.. “Real-world efficacy and adverse events of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase: A prospective multicenter study from SCCCG[PLUS]-CML 2023.” Cancer (2025). PMID: 41405208 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
  260. [260]

    Sy SKB, Yang Y, Darstein C et al.. “Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase.” Cancer chemotherapy and pharmacology (2025). PMID: 40848059 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
  261. [261]

    Cheng F, Wang F, Cui Z et al.. “Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study.” BMC cancer (2026). PMID: 41668074 ↗

    L2COHORTCited in: Prognosis and Prognostic Factors, Special Populations
  262. [262]

    Andrews MC, Turner N, Boyd J et al.. “Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26202951 ↗

    L4CASE_REPORTCited in: Prognosis and Prognostic Factors
  263. [263]

    Kobayashi N, Ono H, Okubo N et al.. “Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.” Annals of nuclear medicine (2026). PMID: 41678086 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors, Special Populations
  264. [264]

    Strathdee G, Holyoake TL, Sim A et al.. “Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17785556 ↗

    L4OTHERCited in: Prognosis and Prognostic Factors
  265. [265]

    Pamuk GE, Chow ECY, Ionan AC et al.. “FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39088257 ↗

    L5OTHERCited in: Special Populations
  266. [266]

    Agarwal A, MacKenzie RJ, Pippa R et al.. “Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24436473 ↗

    L5OTHERCited in: Special Populations
  267. [267]

    Kim DH, Sriharsha L, Xu W et al.. “Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19584153 ↗

    L2OTHERCited in: Special Populations

Revision History

All updates applied to this page

Loading revisions…